Primecap Management Co. CA Sells 412,450 Shares of Illumina, Inc. $ILMN

Primecap Management Co. CA lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 17.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,958,499 shares of the life sciences company’s stock after selling 412,450 shares during the period. Primecap Management Co. CA owned about 1.27% of Illumina worth $186,860,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. KLP Kapitalforvaltning AS lifted its holdings in shares of Illumina by 1.3% in the 1st quarter. KLP Kapitalforvaltning AS now owns 61,045 shares of the life sciences company’s stock worth $4,843,000 after buying an additional 800 shares during the period. Legato Capital Management LLC increased its stake in shares of Illumina by 61.5% during the first quarter. Legato Capital Management LLC now owns 23,600 shares of the life sciences company’s stock valued at $1,872,000 after buying an additional 8,986 shares during the period. AE Wealth Management LLC bought a new stake in shares of Illumina in the first quarter valued at about $2,278,000. Diamond Hill Capital Management Inc. bought a new stake in shares of Illumina in the first quarter valued at about $26,101,000. Finally, Mendel Money Management lifted its stake in Illumina by 22.1% in the first quarter. Mendel Money Management now owns 3,668 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 663 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other news, Director Scott Gottlieb bought 500 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average cost of $122.13 per share, with a total value of $61,065.00. Following the transaction, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.17% of the company’s stock.

Illumina Stock Performance

Shares of ILMN stock opened at $120.12 on Thursday. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06. The business’s fifty day simple moving average is $104.25 and its 200-day simple moving average is $96.90. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. The company has a market cap of $18.35 billion, a PE ratio of 15.21, a PEG ratio of 2.34 and a beta of 1.42.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the business posted $1.14 earnings per share. The firm’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on ILMN. Daiwa America downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 12th. Barclays increased their price objective on shares of Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Daiwa Capital Markets lowered Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 target price for the company. in a report on Tuesday, August 12th. Evercore ISI lifted their price target on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Finally, JPMorgan Chase & Co. boosted their price target on Illumina from $100.00 to $105.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $115.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.